Gastrointestinal Imaging

Which Imaging Is Best for Posttreatment Evaluation of Gastric Adenocarcinoma?

·
Which Imaging Is Best for Posttreatment Evaluation of Gastric Adenocarcinoma?

A 64-year-old male with locally advanced gastric adenocarcinoma has just completed several cycles of neoadjuvant chemotherapy. He is in your clinic today for posttreatment evaluation to determine his response and assess his candidacy for a curative-intent gastrectomy. You need to order imaging that can accurately evaluate the primary tumor, regional lymph nodes, and screen for distant metastases that may have developed. The central question is which study provides the most reliable information to guide the surgical team. According to the American College of Radiology (ACR) Appropriateness Criteria, for this specific clinical scenario, `CT abdomen and pelvis with IV contrast` is rated Usually appropriate.

Who Fits This Clinical Scenario?

This guidance is specifically for an adult patient with a biopsy-proven diagnosis of gastric adenocarcinoma who has completed a course of nonsurgical treatment (such as neoadjuvant chemotherapy, radiation therapy, or chemoradiation) and now requires imaging evaluation. The primary goals of this imaging are to assess the degree of treatment response, determine the current extent of disease, and evaluate for resectability before a planned surgical intervention.

This workflow is distinct from other closely related clinical situations. This article does not apply to:

  • Patients with suspected but undiagnosed gastric cancer: These individuals require initial diagnostic imaging, which falls under the ACR variant for initial imaging of suspected gastric adenocarcinoma.
  • Patients with a new diagnosis requiring initial staging: A newly diagnosed patient who has not yet received any treatment requires baseline staging, a different clinical scenario focused on defining the disease extent from the start.
  • Asymptomatic patients in long-term follow-up: Patients who have already completed all definitive treatments (including surgery) and are now being monitored for recurrence fall under the surveillance guidelines.

Correctly identifying the patient’s place in the care pathway—post-neoadjuvant, pre-surgical—is critical for selecting the most appropriate imaging.

What Diagnoses Are You Working Up in This Scenario?

While the primary diagnosis of gastric adenocarcinoma is already established, posttreatment imaging is not about discovering a new condition. Instead, it’s a critical re-evaluation aimed at answering specific questions about the status of the known cancer. The “differential” in this context is a spectrum of possible treatment outcomes that will dictate the next steps in management.

The key possibilities you are assessing include:

  • Favorable Treatment Response: This is the ideal outcome, where imaging demonstrates a significant reduction in the size and extent of the primary tumor, resolution or decrease in size of involved lymph nodes, and no new sites of disease. This finding supports proceeding with curative-intent surgery. Imaging is looking for decreased gastric wall thickening and downstaging of nodal disease.
  • Stable Disease: In this case, the tumor and any metastatic sites have not significantly changed in size or extent despite therapy. This information is crucial for the multidisciplinary tumor board to decide whether to proceed with surgery, consider alternative systemic therapies, or adjust the treatment plan.
  • Disease Progression: This is the most concerning finding, characterized by an increase in the size of the primary tumor, development of new or enlarging lymph nodes, or the appearance of new distant metastases (e.g., in the liver, lungs, or peritoneum). Identifying progression is critical to avoid the morbidity of a major surgery that is no longer curative.
  • Post-Treatment Fibrosis vs. Residual Tumor: A major challenge for imaging is distinguishing between scar tissue (fibrosis) resulting from successful treatment and small pockets of viable, residual cancer. While imaging can be suggestive, it often cannot provide a definitive distinction, which is why surgery is typically recommended even after a good radiologic response.

Why Is CT Abdomen and Pelvis with IV Contrast the Recommended Study?

For posttreatment evaluation of gastric adenocarcinoma, both `CT abdomen and pelvis with IV contrast` and `FDG-PET/CT skull base to mid-thigh` are rated Usually appropriate by the ACR. CT is often the first-line choice due to its wide availability, speed, and excellent anatomic detail.

The rationale for its high rating includes:

  • Anatomic Detail: Multidetector CT (MDCT) provides high-resolution images of the gastric wall, allowing for assessment of tumor thickness and extension into adjacent structures. Proper gastric distention, often achieved with water as a neutral oral contrast agent, is a key technical parameter.
  • Nodal and Metastatic Evaluation: IV contrast-enhanced CT is highly effective for identifying and measuring regional lymph nodes and for detecting common sites of distant metastases, particularly in the liver and peritoneum. The enhancement patterns help characterize suspicious lesions.
  • Vascular Assessment: The arterial and portal venous phases of a multiphasic CT protocol are essential for evaluating the tumor’s relationship to major blood vessels, a critical factor in determining surgical resectability.

While CT is excellent, `FDG-PET/CT` also plays a vital role. It adds metabolic information to the anatomic detail from CT, which can be particularly useful for identifying viable tumor within post-treatment scar tissue and detecting small or unexpected metastatic deposits that may not be apparent on CT alone. The choice between CT and PET/CT often depends on institutional protocols, the findings on pre-treatment imaging, and the specific clinical question being asked.

Why are other studies rated lower for this scenario?

  • MRI abdomen and pelvis without and with IV contrast is rated May be appropriate. While it offers excellent soft tissue contrast and can be a superior problem-solving tool for indeterminate liver lesions, it is generally more time-consuming and less available than CT. It serves as a strong alternative for patients with contraindications to iodinated CT contrast.
  • US abdomen is rated Usually not appropriate. Ultrasound is severely limited by bowel gas, which obscures the stomach and surrounding structures. It cannot provide the comprehensive assessment of the primary tumor, regional nodes, and distant metastases required for posttreatment re-staging.

Both CT and PET/CT involve ionizing radiation. CT of the abdomen and pelvis carries a relative radiation level of ☢☢☢ (1-10 mSv), while a diagnostic FDG-PET/CT is higher at ☢☢☢☢ (10-30 mSv). This trade-off should be considered in the context of the critical information needed to guide cancer therapy.

Once you’ve decided on CT, our protocol guide covers the technique, contrast, and reading principles: CT Chest/Abdomen/Pelvis with IV Contrast.

What’s Next After CT Abdomen and Pelvis with IV Contrast? Downstream Workflow

The results of the posttreatment CT scan directly influence the patient’s subsequent management, typically determined in a multidisciplinary tumor board meeting.

  • If the scan shows a good response and resectable disease: The patient is confirmed as a candidate for surgery. The next step is surgical consultation to plan for a gastrectomy with lymph node dissection. The imaging provides a crucial roadmap for the surgeon.
  • If the scan shows disease progression (local or distant): This is a significant finding that often changes the goal of therapy from curative to palliative. The patient would typically not proceed to surgery. Instead, the oncology team will consider second-line systemic therapies, palliative radiation, or best supportive care.
  • If the scan shows stable disease: This is an ambiguous scenario. The decision to proceed with surgery depends on the patient’s overall performance status, the resectability of the tumor at baseline, and the consensus of the tumor board. In some cases, surgery may still be offered, while in others, a different systemic therapy may be tried.
  • If the scan is indeterminate (e.g., a new, small liver lesion): An indeterminate finding may require further workup before a final decision can be made. This often involves a problem-solving study like an MRI (a May be appropriate option) to better characterize the lesion or, in some cases, a percutaneous biopsy.

Pitfalls to Avoid (and When to Get Help)

Navigating posttreatment imaging requires careful attention to detail to avoid common errors that can impact patient care.

  • Forgetting Gastric Distention: A collapsed stomach can mimic or obscure residual tumor. Always specify in the order that a gastric distention protocol (e.g., with water) is required.
  • Omitting IV Contrast: A non-contrast CT is inadequate for this indication. It cannot assess tumor enhancement, evaluate lymph nodes properly, or detect liver metastases effectively.
  • Misinterpreting Post-Treatment Inflammation: Radiation and chemotherapy can cause inflammatory changes that may be mistaken for residual or progressive disease. Comparing with the pre-treatment scan is essential to assess for true change.

If the imaging findings are equivocal or do not align with the patient’s clinical picture, immediate discussion with the reporting radiologist and presentation at a multidisciplinary tumor board are the most appropriate next steps.

Related ACR Topics and Tools

For a comprehensive overview of imaging across all clinical variants related to this condition, from initial diagnosis to long-term surveillance, please consult our parent topic guide.

Frequently Asked Questions

Why is PET/CT also ‘Usually Appropriate’ for posttreatment evaluation of gastric cancer?

FDG-PET/CT is also rated ‘Usually appropriate’ because it provides metabolic information that complements the anatomic detail of CT. It can be more sensitive for detecting viable tumor cells within post-treatment scar tissue and for identifying small metastatic deposits, particularly in lymph nodes or the peritoneum, that may not be enlarged on CT. The choice between CT and PET/CT often depends on the pre-treatment findings and institutional preference.

Is an MRI a good alternative if my patient cannot receive iodinated CT contrast?

Yes. MRI of the abdomen and pelvis with and without IV contrast is rated ‘May be appropriate’ and is an excellent alternative for patients with severe allergies to iodinated contrast or with renal insufficiency. It provides high-quality soft-tissue imaging and is particularly strong for characterizing liver lesions, though it may be less effective at evaluating subtle peritoneal disease compared to a high-quality CT.

If the CT shows a complete response, can the patient skip surgery?

No, a complete radiologic response does not guarantee a complete pathologic response. Microscopic residual disease often remains even when the tumor is no longer visible on CT or PET/CT. Therefore, surgery (gastrectomy) is typically still recommended to achieve the best chance for a cure.

Should I order a CT of the chest in addition to the abdomen and pelvis?

Yes, in most cases, a concurrent CT of the chest is recommended for complete staging. Although the abdomen and pelvis are the primary areas of concern, the lungs are a potential site of distant metastasis for gastric cancer. Most institutional protocols for gastric cancer staging will include the chest.

What is the role of endoscopic ultrasound (EUS) in posttreatment evaluation?

Endoscopic ultrasound (EUS) is rated ‘Usually not appropriate’ for posttreatment evaluation. While EUS is excellent for initial local (T and N) staging, its accuracy is significantly reduced after neoadjuvant therapy. Post-treatment inflammation and fibrosis make it very difficult to distinguish scar tissue from residual tumor, limiting its utility in this specific scenario.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026